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Only a few years ago it was demonstrated that mammalian DNA contains oxidized forms of 5-methylcytosine
(5mC). The base 5-hydroxymethylcytosine (5hmC) is the most abundant of these oxidation products and is referred
to as the sixth DNA base. 5hmC is produced from 5mC in an enzymatic pathway involving three 5mC oxidases,
Ten-eleven translocation (TET)1, TET2, and TET3. The biological role of 5hmC is still unclear. Current models propose
that 5hmC is an intermediate base in an active or passive DNA demethylation process that operates during
important reprogramming phases of mammalian development. Tumors originating in various human tissues have
strongly depleted levels of 5hmC. Apparently, 5hmC cannot be maintained in proliferating cells. Furthermore,
mutations in the TET2 gene are commonly observed in human myeloid malignancies. Since TET proteins and many
lysine demethylases require 2-oxoglutarate as a cofactor, aberrations in cofactor biochemical pathways, including
mutations in isocitrate dehydrogenase (IDH), may affect levels of 5hmC and 5mC in certain types of tumors, either
directly or indirectly. We discuss current data and models of the function of 5hmC in general, with special emphasis
on its role in mechanisms of development and cancer.Introduction
5-methylcytosine (5mC) is created in a postreplicative
enzymatic reaction in which a DNA methyltransferase
enzyme transfers a methyl group from S-adenosylmethio-
nine onto the 5-carbon of cytosine, mostly within the CpG
sequence context [1]. Presence of 5mC at gene promoters
is most often linked to transcriptional repression [2]. It was
long thought that 5mC was the only modified base in
animal DNA. 5-hydroxymethylcytosine (5hmC) was initially
found in the DNA of certain bacteriophages [3] and was
reported in mammalian tissues as early as 1972 [4]. How-
ever, the levels reported by Penn et al. [4] seemed too high
and could not be confirmed in subsequent studies [5]. The
earlier report by Penn et al. [4] had put the levels of 5hmC
in brain and liver DNA at 15% of the level of cytosine,
which is at least an order of magnitude higher than
currently established levels for brain and around two orders
of magnitude higher than levels found in liver DNA [6].
Also, in the same study, 5mC was not detected casting
doubt on these earlier results.* Correspondence: gpfeifer@coh.org
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reproduction in any medium, provided the orIt was not until 2009 that the existence of 5hmC in
mammalian cells was unambiguously proven [7,8]. By
homology searches against a bacteriophage protein that
oxidizes thymine in DNA, Tahiliani et al. [8] discovered
three proteins, Ten-eleven translocation 1–3 (TET1-3),
in mammalian genomes as candidate 5mC oxidases and
confirmed such activity for TET1, a gene/protein earlier
implicated in a translocation in a myeloid leukemia
patient [9]. These discoveries were breakthroughs in the
field of mammalian epigenetics.
Review
Dual role of 5-hydroxymethylcytosine as a stable DNA
base and as an intermediate in DNA demethylation
We now know that 5hmC levels vary substantially be-
tween different cell types and tissues and are highest in
the brain, in particular in neurons [6,7,10-12]. Because
5hmC is an oxidation product of 5mC, it is clear that
formation of 5hmC from 5mC automatically lowers the
levels of 5mC at any given nucleotide position or even
genome-wide. Therefore, it was immediately apparent
that the conversion of 5mC into 5hmC could be the first
step in a pathway leading towards DNA demethylation.
There is evidence from various experimental systems
that this may indeed be the case [13,14]. The end resultLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Figure 1 Chemical structures of 5-methylcytosine (5mC) and
its oxidation products 5-hydroxymethylcytosine (5hmC),
5-formylcytosine (5fC) and 5-carboxylcytosine (5caC). The
potential involvement of these modified cytosine bases in several
pathways of passive (replication-dependent) and active
(replication-independent) DNA demethylation is indicated. One
active demethylation pathway is proposed to include consecutive
oxidation steps followed by removal of 5caC by thymine DNA
glycosylase (TDG) in a base excision repair (BER) scheme or by
decarboxylation arriving back at cytosine (C). DNMT,
DNA methyltransferase.
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moval of the modified base and/or disappearance of the
methyl group from cytosine in DNA (Figure 1). In the
passive demethylation pathway, 5hmC cannot be copied
by the maintenance DNA methyltransferase, DNMT1,
an enzyme that propagates pre-existing methylation pat-
terns and operates on hemimethylated CpG sites [15,16].
The active demethylation process that uses 5hmC as an
intermediate is considerably more complicated. One re-
port suggested that 5hmC can be converted to cytosine
by DNA methyltransferases [17]. Deamination of 5hmC
produces 5-hydroxymethyluracil [18], which can be
removed by base excision repair enzymes including
thymine DNA glycosylase (TDG) [19,20] and single-
strand selective monofunctional uracil DNA glycosylase
(SMUG1) [21]. However, how effectively such a pathway
is operative in vivo is currently unknown. Stepwise
oxidation of 5hmC by TET proteins produces 5-
formylcytosine (5fC) and then 5-carboxylcytosine (5caC)
[22,23]. This 5caC, which is detectable at low levels in
DNA, can then be removed either by base excision re-
pair catalyzed by the DNA glycosylase activity of the
protein TDG [23], or by decarboxylation. Theoretically,
the decarboxylation pathway should be favorable as itdoes not require breakage of the DNA phosphodiester
bonds, which occurs during TDG-initiated base excision
repair. However, to date, no enzymatic activity for the
decarboxylation step has been identified although de-
carboxylation does seem to occur [24].
Many tissues accumulate quite substantial levels of
5hmC, much greater than would be expected if this base
were simply a transient intermediate in a sequential oxi-
dation pathway leading towards DNA demethylation.
Therefore, 5hmC may be an epigenetic module that has
its own unique biochemical coding properties. This
function may be a negative or repulsive one since oxida-
tion of the methyl group during production of 5hmC
will block binding of proteins that would otherwise
interact with 5mC [25]. Alternatively, its function may
be a positive or instructive one if proteins exist that spe-
cifically bind to 5hmC. So far, several different proteins
have shown ability to recognize 5hmC, at least in vitro,
including UHRF1 [26], MBD3 [27], MeCP2 [28], and
several others identified by a proteomics approach [29].
However, the biological role of their binding to 5hmC is
still not entirely clear. Most of these proteins have other
functions as well, and therefore may not be uniquely
designed to interact with 5hmC.
The role of 5-hydroxymethylcytosine in mammalian
development and differentiation
The functional role of 5hmC in mammalian genomes is
still unclear. At the beginning of the mammalian life
cycle, upon fertilization of oocytes by sperm, most of the
5mC in the paternal (sperm-derived) genome becomes
oxidized to form 5hmC [30,31]. This oxidation step,
which previously had been thought to reflect true DNA
‘demethylation’ [32,33], is specific to the paternal gen-
ome whereas the maternal (oocyte-derived) genome re-
mains protected from Tet-catalyzed oxidation [34,35].
Paternal genome oxidation is catalyzed by Tet3, encoded
by the only Tet gene expressed at substantial levels in
oocytes and zygotes [30]. Genetic knockout of Tet3 in
mice results in failed paternal genome oxidation,
compromised development and perinatal lethality [36].
Another important developmental transition involves
global DNA demethylation in primordial germ cells
(PGCs) that commences at around embryonic day 8.5 to
9.5 and is completed near embryonic day 13.5. The
mechanisms of methylation erasure in PGCs have
remained largely unclear and controversial. It has long
been assumed that replication-independent active DNA
demethylation is a key pathway likely involved in this
step [37,38]. However, more recent data favor a passive
loss of methylation caused by lack of methylation main-
tenance during DNA replication [39-41]. This passive
loss of 5mC may be effectively initiated by conversion of
5mC into 5hmC [42]. Tet1 and Tet2 are the 5mC
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[36,43]. Progeny of mice deficient in Tet1 and Tet2 have
deficiencies in DNA demethylation at imprinted genes
[44]. However, Tet1/2-deficient animals of both sexes
were fertile, with females having smaller ovaries and re-
duced fertility. Deletion of Tet1 and Tet2 can produce
viable adults, although the majority of such mice die
during embryogenesis or around birth and show various
developmental defects [44]. The data suggest that Tet1/
2-induced 5mC oxidation in PGCs is not absolutely re-
quired for producing viable offspring. The currently
available information on DNA demethylation in zygotes
and in PGCs still lacks a more specific analysis of 5hmC
at the DNA sequence level, as can be accomplished, for
example, by TAB-sequencing [45]. It is expected that
such information will clarify the global or locus-specific
involvement of 5hmC formation in the initiation of pas-
sive (or active) DNA demethylation. The previous impli-
cation of base excision repair processes in germ line
reprogramming [43,46], which by itself would pose a tre-
mendous risk for maintenance of genome integrity if op-
erative at a global level, may have various other
explanations. In one scenario, the occurrence of base ex-
cision repair activity might be explained by the require-
ment to counteract spurious non-targeted oxidation
reactions catalyzed by Tet oxidase activity on guanines
at methylated CpG sites (guanine being the DNA base
most susceptible to oxidation). In another setting, 5hmC
may be oxidized further, perhaps at specific sequences,
by Tet proteins to form 5caC, which is then removed by
base excision repair initiated by TDG [23].
Because 5hmC is most abundant in brain tissue, it has
become a priority to understand the function of this
modified base in the brain. For example, in DNA from
human brain cortex, the level of 5hmC is about 1% of all
cytosines or 20 to 25% of all 5mC bases [47]. This corre-
sponds to approximately 6,000,000 5hmC bases per hap-
loid genome. Clearly these levels suggest that 5hmC has
an important functional role in the mammalian brain.
Studies reported so far have shown that 5hmC in brain
tissues is very abundant within gene regions, either at
promoters or even more so within intragenic regions,
the so-called gene bodies [10,12,48]. It is conceivable
that the formation of 5hmC at promoters, CpG islands
or CpG island shores (edges) functions analogous to a
repair process to oxidize and eventually remove inappro-
priately introduced 5mCs in these regions [10,49]. De-
position of 5hmC in promoters [50] or gene bodies
[10,12,51] often correlates positively with gene activity.
The mechanism of how gene body-associated 5hmC in-
creases transcript levels is currently unknown. One pos-
sibility is that 5mC oxidation releases a repressive effect
on transcription, perhaps by counteracting spurious in-
tragenic anti-sense transcription. Other explanationsmay include the fact that 5hmC has a destabilizing effect
on DNA structure [52,53] that potentially favors the
opening of the double helix by the transcription
apparatus.
5hmC, although not recognized by several methyl-
CpG binding proteins, including MBD1, MBD2 and
MBD4 [25], is able to bind MeCP2 [28], a methyl-CpG-
binding protein that is abundant in the brain and is
mutated in the neurological disorder Rett syndrome
[54]. Earlier studies, using the methyl-CpG binding do-
main (MBD) of MeCP2 rather than the full-length pro-
tein, did not conclude that MeCP2 binds to 5hmC [55].
The reasons for these discrepancies are not clear. The
connection between MeCP2 and 5hmC in the brain is of
particular interest since levels of 5hmC are highest in
the brain and MeCP2 is an abundant protein in the
brain reaching levels similar to that of histone H1. For
these reasons, a genome-wide rather than sequence-
specific mechanistic role of 5hmC-binding by MeCP2
can be anticipated in the brain.
As shown recently, formation of 5hmC is critical for
brain development. The base is abundant in developing
neurons in which its level increases relative to neural
progenitor cells and where it specifically localizes to
gene bodies of genes important for neuronal differenti-
ation [56]. Tet3 is most highly expressed in the develop-
ing mouse brain cortex followed by Tet2 and the levels
of Tet1 are very low in this tissue. An increase in the
levels of Tet2, Tet3 and 5hmC in differentiating neurons
coincides with reduction of the Polycomb H3K27
methyltransferase Ezh2 and loss of H3K27me3 at critical
genes. Reducing the levels of Tet2 and Tet3 or increasing
Ezh2 expression results in incomplete or blocked neur-
onal differentiation [56]. Thus, formation of 5hmC pro-
motes neuronal differentiation by modulating the
expression of genes most critical in this important devel-
opmental transition.
Loss of 5-hydroxymethylcytosine in cancer
The levels of 5hmC in cancer are strongly reduced rela-
tive to the corresponding normal tissue surrounding the
tumor [47]. Using liquid chromatography-mass spec-
trometry, anti-5hmC antibody-based immuno-dot blots
and immunohistochemistry, we demonstrated tumor-
associated loss of 5hmC for cancers of the lung, brain,
breast, liver, kidney, prostate, intestine, uterus and mel-
anoma [47]. Other investigators confirmed this observa-
tion by showing loss of 5hmC in different types of solid
tumors [57-60]. Moreover, reintroduction of TET2 has
been shown to restore 5hmC levels and decrease meta-
static potential of melanoma cells [61]. Strikingly, when
we co-immuno-stained tissue sections with antibodies
against 5hmC and against the Ki67 antigen, which is a
marker found only in proliferating cells, we observed
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eously in a single cell [47]. At a clinical diagnostic level,
combined immunohistochemical analysis of 5hmC loss
and presence of Ki67-positive cells could be developed
into a biomarker for cancer diagnosis. The lack of, or
strong reduction of, 5hmC in tumors suggests that pro-
liferating cells lose 5hmC. In most cases, the bulk tumor
mass is depleted of 5hmC even when Ki67-positive cells
are rare, suggesting that these tumor cells have had a
past history of proliferation leading to loss of 5hmC,
which is then not re-established [47]. The replication-
dependent loss of 5hmC reflects a situation reminiscent
of the one in preimplantation embryos in which initial
formation of 5hmC in the paternal DNA is followed by
replication-dependent loss or dilution of this mark
[30,62]. Similarly, global 5hmC content decreases rapidly
as cells from normal tissue adapt to cell culture [51].
The simplest explanation is that oxidation of 5mC pro-
duces a hemi-hydroxymethylated CpG site in DNA that
is not recognized by DNMT1 during DNA replication.
Such an explanation is consistent with in vitro studies
showing that DNMT1 is unable to operate on CpG sites
that contain 5hmC [15,16]. However, other explanations
for the reduction of 5hmC in cancer are also possible.
The levels of TET proteins may be lower in tumor tissue
than in its matching normal tissue counterpart. Al-
though we did not observe consistent differences at the
RNA level for TET1, TET2, or TET3 in lung and brain
tumors relative to normal tissue [47], others have
reported lower levels of TET gene expression in cancer
[58,60]. An additional possibility is that cancer cells con-
tain compromised metabolic pathways that are involved
in production of the co-factor for TET activity, 2-
oxoglutarate (see below).
Mutation of TET2 in human cancer
TET1 belongs to a family of proteins characterized as
promoting the conversion of 5mC to 5hmC in mamma-
lian DNA [8,63]. There are three identified family mem-
bers belonging to the TET family: TET1, TET2, and
TET3. TET1 is located on human chromosome 10q21.3,
while TET2 is located on chromosome 4q24 and TET3
is on chromosome 2p13.1. The TET1 enzyme consists of
a zinc finger CXXC DNA binding domain, a cysteine-
rich region, and a 2-oxoglutarate- and iron (II)-
dependent dioxygenase (2OGFeDO) domain [8,64].
TET3 also contains an N-terminal CXXC domain [65].
However, the TET2 gene underwent a chromosomal
gene inversion during evolution, thus separating its
CXXC domain from the catalytic domain and creating a
new CXXC domain gene named IDAX/CXXC4, which
encodes a negative regulator of TET2 [66]. Based on
EST profiles and expression arrays, TET1 shows greatest
expression during embryogenesis and does not showrelevant expression in adult tissues. TET2 is mostly
expressed in hematopoietic cells and TET3 seems ubi-
quitously expressed in adult human tissues.
Leukemia is a disease where, during normal
hematopoietic stem cell differentiation, clonal expansion
of hematopoietic precursor cells in the bone marrow is
affected at a certain stage of differentiation, causing an
imbalance between differentiation and self-renewal. In-
appropriate expansion of hematopoietic progenitor cells
is primarily caused by a blockage of cell maturation.
Myelodysplastic syndrome (MDS) disorders in hemato-
poiesis are characterized by cytopenia (low blood cell
count), ineffective hematopoiesis in one cell lineage or
another, and an increased risk of transformation to acute
myeloid leukemia (AML) [67]. In AML, rapid growth of
abnormal white blood cells in the bone marrow leads to
a blockage in the production of various cells from other
cell lineages.
TET2 has been found mutated in patients with myelo-
proliferative neoplasms (MPN), MDS, AML and chronic
myelomonocytic leukemia (CMML), and is the most
commonly mutated gene in MDS [68-72]. Mutations of
TET1 or TET3 are not observed in MDS nor does the
TET2 mutation correlate with several other known com-
mon mutations [68]. Interestingly, isocitrate dehydro-
genase 1/2 (IDH1/2) mutations are rarely found together
with TET2 mutations, but have similar effects as TET2
mutations on hematopoietic stem cells (HSCs) [73].
While TET2 mutations are associated with reduced over-
all survival in AML compared to patients with wild-type
TET2, TET2 mutations in MDS and MPN patients pro-
mote progression to AML [68]. The TET2 gene is com-
prised of a total of eleven exons, translating into a 2002
amino acid protein product [70]. TET2 mutations in
myeloid cancers have been most commonly observed
within exons 3a and 10, which are the longest exons
[71]. Both multipotent and committed progenitor cells
in the hematopoietic lineage are targeted by TET2 muta-
tions in MPN, implying that TET2 plays an important
role in myelopoiesis [69]. Deletions of TET2 and loss of
heterozygosity or uni-parental disomy was observed in
(9%) MDS/AML patients with mutated TET2 [70],
where it is likely for the wild-type allele to be lost during
recombination, allowing mutated TET2 to promote a
loss of function phenotype. Kosmider et al. [70] ob-
served that 50% of patients with mutated TET2 had gen-
etic defects that targeted the two TET2 copies.
Mutations in TET2 seem to lead to loss of function,
suggesting that it may play a tumor suppressive role.
Understanding the underlying implications of mutant
TET2 lacking function and its role in myeloid malignan-
cies is a current research priority. Several laboratories
generated conditional Tet2 knockout mouse models
[74-77] in which critical Tet2 exons were targeted.
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veloped splenomegaly at 20 weeks of age, showing phe-
notypes similar to those observed in human CMML
patients with mutant TET2. The data from the different
mouse models led to similar observations. Deleting Tet2
is not embryonic lethal. A major observation made by
Moran-Crusio et al. [74] and by Ko et al. [77] is that
hematopoietic stem cells from Tet2−/− mice have an in-
creased ability to repopulate the hematopoietic compart-
ment in vivo during competitive reconstitution assays
with competition from HSCs from Tet2+/+ cells. Analysis
of various organs of Tet2−/− mice showed that loss of
Tet2 is not compensated by an increase in Tet1 or Tet3
expression [75,77]. 5hmC levels are significantly de-
creased in bone marrow and spleen of Tet2−/− mice
[75,77]. Tet2−/− mice show an increase in HSCs with a
slight increase in myeloid progenitors, skewing hemato-
poiesis towards monocyte/macrophage cell fates [74-77].
It is suggested that an active Tet2 would regulate normal
hematopoiesis to assure proper lineage distribution and
controlled differentiation of HSCs. Of particular interest
is the effect of TET2 mutations on levels and patterns of
5mC in the genome. However, the current data are far
from clear. Whereas one report indicated that TET2
mutation in AML is associated with a DNA hyper-
methylation phenotype [73], other data suggested that
bone marrow samples from patients with TET2 muta-
tions have low 5hmC levels and DNA hypomethylation
[78,79]. The situation is complicated by the fact that
hematopoietic malignancies are often characterized by
mutations in several epigenetic modifiers including
EZH2, IDH1, IDH2, MLL, DNMT3A, and ASXL1, thus
potentially obscuring any straightforward associationsFigure 2 Production of 2-oxoglutarate by isocitrate dehydrogenase. 2
which oxidize 5-methylcytosine (5mC) to 5-hydroxymethylcytosine (5hmC).
2-hydroxyglutarate (2HG), a competitive inhibitor of 2-oxoglutarate-depend
other 2-oxoglutarate-dependent enzymes by 2HG may affect patterns of 5m[80]. For example, in one study, eight of eleven patients
with DNMT3A mutations (73%) in T-cell lymphoma also
had TET2 mutations [81].
Mutations in co-factor pathways
5mC oxidases are 2-oxoglutarate-dependent enzymes
(Figure 2). This cofactor is produced in the tricarboxylic
acid cycle from isocitrate by the enzyme IDH. Interest-
ingly, several types of human tumors contain mutations
in the IDH1 gene. IDH1 mutations are particularly fre-
quent in grade II and III gliomas where they are found
in up to 70% of the patients [82]. Mutations in IDH1
and IDH2 are also seen in myeloid leukemias and a few
other malignancies but at a lower frequency [73,83].
These IDH1 mutations are not scattered throughout the
gene but are almost exclusively found at amino acid pos-
ition 132. This finding suggests that this particular IDH1
mutant protein has a gain of function property. A sur-
prising discovery was that the IDH1 codon 132 arginine
to histidine mutant produces the oncometabolite 2-
hydroxyglutarate (2HG) as a reaction product instead of
2-oxoglutarate [84]. It seems that the isocitrate oxidation
reaction carried out by this mutant is incomplete and
produces 2HG only. Furthermore, 2HG is a competitive
inhibitor of many, if not all, 2-oxoglutarate-dependent
enzymatic activities. The TET proteins represent one
class of such enzymes, and it was shown that 2HG is an
inhibitor of TET1 and TET2 [85].
One interesting correlate of having mutated IDH1 in
glioma tumors is that the IDH1-mutant tumors are al-
most always associated with abundant genome-wide
changes in DNA methylation as indicated by widespread
hypermethylation of CpG islands [86]. This phenotype-oxoglutarate is a cofactor for Ten-eleven translocation (TET) proteins,
The isocitrate dehydrogenase (IDH)1 mutant R132H produces
ent enzymes including TET proteins. The inhibition of TET activity or of
C in the genome of IDH1 mutant cells.
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type (or CIMP) [87]. It is tempting to presume that
CIMP in IDH1-mutant gliomas is linked to a failure of
5hmC production in these tumors because TET activity
is compromised by 2HG. In fact, experimental introduc-
tion of an IDH1 mutant construct into human astrocytes
led to the emergence of a CIMP-like phenotype [88].
Furthermore, in conditional knock-in mice in which the
most common Idh1 mutant R132H was inserted into the
endogenous Idh1 locus and was expressed in hema-
topoietic cells, DNA hypermethylation was observed
[89]. However, in a direct comparison of 5hmC levels in
DNA between IDH1 mutant and IDH1 wild-type
gliomas, we did not observe any substantial differences
between these two categories of brain tumors [47].
Therefore, one needs to keep in mind that mutant IDH1
and its metabolite product 2HG not only affect TET
enzymes but also inhibit many lysine demethylases that
depend on 2-oxoglutarate and other 2-oxoglutarate-
dependent enzymes. The dysfunction of these lysine
demethylases may have a secondary impact on DNA
methylation patterns at CpG islands.
Conclusion
Emerging data suggest that the DNA base 5hmC has
functional roles in gene regulation and development.
Many details are not yet understood at a sufficient level.
Because of the abundance of 5hmC in brain tissue, a
specific function of this base in the brain is most plaus-
ible. However, 5hmC occurs also in other tissues. Add-
itional studies will be required to examine its
distribution in different tissue types to determine if this
base has a more general role in gene control. Single
base-level analysis of 5hmC is now possible [45] allowing
for a more precise mapping of this base modification in
the genome. Additional proteins interacting uniquely
with 5hmC will need to be identified. A key question is
whether such proteins provide a functional readout to
5hmC by linking the base to mechanistic pathways in
chromatin biology. The exact role of 5hmC in DNA de-
methylation needs more evidence to clearly support such
a role. One possibility is that localized loss of 5hmC cre-
ated by local defects in 5mC oxidation could shift the
balance of methylated versus unmethylated cytosines
within CpG islands towards the hypermethylated state. If
this were the case, a mechanistic explanation for the
widespread cancer-associated DNA hypermethylation
would be at hand. However, current data suggest that
the loss of 5hmC in cancer occurs at a more global scale.
How the genome-wide loss of this base could be tied,
directly or indirectly, to the prevalent phenomenon of
CpG-island hypermethylation in cancer will be an inter-
esting aspect of future studies. At a more practical level,
the loss of 5hmC as observed in tumor cells could beused in diagnostic procedures to identify early-stage ma-
lignant disease.
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